Group One Trading
NAMS icon

Group One Trading’s NewAmsterdam Pharma NAMS Stock Holding History

Group One Trading’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Hold
500
– – ﹤0.01% 6097
2025
Q4 		$17.5K Buy
+500
New +$18.2K ﹤0.01% 6450
2025
Q2 		– Sell
-5,000
Closed -$102K – 8398
2025
Q1 		$102K Buy
+5,000
New +$111K ﹤0.01% 4585

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Group One Trading's NAMS Position: Q1 2026 in Review

Group One Trading sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 1,313 shares — an estimated $42.8K sold.

Group One Trading first reported a position in NAMS in Q4 2024 and held it in 4 quarters. The position peaked at $46.1K in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Group One Trading reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 1,313 NewAmsterdam Pharma shares in Q1 2026, an estimated $42.8K.
  • Group One Trading first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 4 quarters.
  • Group One Trading's NewAmsterdam Pharma position peaked at $46.1K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.